On December 28, 2021, the FDA updated the emergency use authorization (EUA) for COVID-19 convalescent plasma. The update limits the authorization to the use of COVID-19 convalescent plasma with high titers of anti -SARS-CoV-2 antibodies for the treatment of COVID-19 in patients with immunosuppressive disease or who are receiving immunosuppressive treatment. Additionally, to help assure the manufacture of high titer COVID-19 convalescent plasma, the revisions to the EUA define acceptable tests and increase qualifying result cutoffs to be used for manufacturing COVID-19 convalescent plasma with high titers of anti-SARS-CoV-2 antibodies.
We are currently evaluating our options to determine if we can provide additional testing services using one of the newly defined assays. Please reach out to your customer service manager if your organization is considering CCP testing under the updated guidelines.
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
On April 29, 2019, CTS will begin performing Donor-Screen HLA® Class I and II testing on the Str...
Creative Testing Solutions, the largest nonprofit blood testing organization in the U.S., today anno...
Josh Moon has been appointed Chief Operating Officer (COO) at Creative Testing Solutions (CTS), effe...
We received an updated WNV package insert; please note the manufacturer and license number has been ...
As an organization dedicated to the safety of the world’s blood and plasma supply, Creative Testing...